Advertisement

Stellung der ACE-Hemmer bei der Behandlung kardiovaskulärer Erkrankungen — Gegenwart und Zukunft

  • K. O. Stumpe
Conference paper
  • 9 Downloads

Zusammenfassung

Die Einführung der ACE-Hemmer in die klinische Medizin ist ein Beispiel für eine zielgerichtete pharmakologische Entwicklung und stellt ein völlig neues, pathophysiologisch sinnvolles Prinzip für die Behandlung der arteriellen Hypertonie und der Herzinsuffizienz dar [1, 2]. Aufgrund der Erfahrungen, die in den vergangenen 12 Jahren mit dieser Therapie in der praktischen Medizin gewonnen wurden, werden ACE-Hemmer heute neben Kalziumantagonisten, β-Rezeptorenblockern, Diuretika und postsynaptischen α-Blockern zur Initialbehandlung von hypertensiven Patienten eingesetzt [3].

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Cushman DW, Cheung HS, Sabo EF, Ondetti MA (1977) Design of potent competitive inhibitors of angiotensin-converting enzyme. Biochemistry 16: 5484–5487PubMedCrossRefGoogle Scholar
  2. 2.
    Cushman DW, Cheung HS, Sabo EF, Ondetti MA (1978) Design of new antihypertensive drugs: Potent and specific inhibitors of angiotensin-converting enzyme. Progr Cardiovase Dis 21: 176–180CrossRefGoogle Scholar
  3. 3.
    Joint National Committee (1988) The 1988 report of the Joint National Committee for the detection, evaluation, and treatment of high blood pressure. Arch Intern Med 148: 1023–1038Google Scholar
  4. 4.
    Stumpe KO, Overlack A, Kolloch R, Schreyer S (1982) Longterm efficacy of angiotensin-converting enzyme inhibition with captopril in mild—moderate essential hypertension. Br J Clin Pharmacol 14: 121S - 126SPubMedCrossRefGoogle Scholar
  5. 5.
    Imai Y, Abe K, Seino M, Haruyama T, Tajiama J, Sato M, Goto T et al. (1982) Attenuation of pressor response to norepinephrine and vasopressin by captopril in human subjects. Hypertension 4: 444–450PubMedCrossRefGoogle Scholar
  6. 6.
    Warren SE, O’Connor DT, Cohen IM (1983) Autonomic and baroreflex function after captopril in hypertension. Am Heart 105: 1002–1007CrossRefGoogle Scholar
  7. 7.
    Cody RJ jr, Franklin KW, Laragh JH (1982) Postural hypertension during tilt with chronic captopril and diuretic therapy of severe congestive heart failure. Am Heart J 103: 480–486PubMedCrossRefGoogle Scholar
  8. 8.
    Anderson S, Rennke HG, Brenner BM (1986) Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal diseases associated with systemic hypertension in the rat. J Clin Invest 77: 1993–2000PubMedCrossRefGoogle Scholar
  9. 9.
    Taguma Y, Kitamoto Y, Futaki G, Ueda H, Monma H, Ishizaki M, Takahashi H, Sekino H, Sasaki Y (1985) Effect of captopril on heavy proteinuria in azotemic diabetics. N Engl J Med 313: 1617–1620PubMedCrossRefGoogle Scholar
  10. 10.
    Asmar RG, Pannier B, Santoni J-Ph, Laurent S, London GM, Levy BI, Safar ME (1988) Reversion of cardiac hypertrophy and reduced arterial compliance after converting enzyme inhibition in essential hypertension. Circulation 78: 941–948PubMedCrossRefGoogle Scholar
  11. 11.
    Fröhlich ED, Cooper RA, Lewis EJ (1984) Review of the overall experience of captopril in hypertension. Arch Intern Med 144: 1441–1444PubMedCrossRefGoogle Scholar
  12. 12.
    Ventura HO, Fröhlich ED, Messerli FH, Kobrin I, Kardon MB (1985) Cardiovascular effects and regional blood flow distribution associated with angiotensin converting enzyme inhibition (captopril) in essential hypertension. Am J Cardiol 55: 1023–1026PubMedCrossRefGoogle Scholar
  13. 13.
    Dunn FG, Oigman W, Ventura HO, Messerli FH, Kobrin I, Fröhlich ED (1984) Enalapril improves systemic and renal hemodynamics and allows regression of left ventricular mass in essential hypertension. Am J Cardiol 2: 57–61Google Scholar
  14. 14.
    Christensen KL, Jespersen LT, Mulvany MJ (1989) Development of blood pressure in spontaneously hypertensive rats after withdrawal of long-term treatment related to vascular structure. J Hypertension 7: 83–90CrossRefGoogle Scholar
  15. 15.
    Levy BI, Michel JB, Salzmann JL, Devissaguet M, Camilleri JP, Safar ME (1989) Effects of chronic converting enzyme inhibition on the structure and function of large arteries in the rat. Clin Exp (Theory and Practice) A 11 (Suppl 2): 487–498Google Scholar
  16. 16.
    Ferrannini E, Buzzigoli G, Bonadonna R (1987) Insulin resistance in essential hypertension. N Engl J Med 317: 350–357PubMedCrossRefGoogle Scholar
  17. 17.
    Pollare T, Lithell H, Berne C (1989) A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension. N Engl J Med 321: 868–873PubMedCrossRefGoogle Scholar
  18. 18.
    Pollare T, Lithell H, Selinus I, Berne C (1989) Sensitivity to insulin during treatment with atenolol and metroprolol: a randomized, double-blind-study of effects on carbohydrate and lipoprotein metabolism in hypertensive patients. Br Med J 298: 1152–1157CrossRefGoogle Scholar
  19. 19.
    MacMahon SW, Cutler JA, Furberg CD, Payne GH (1989) The effects of drug treatment for hypertension on morbidity and mortality from cardiovascular disease: a review of randomized controlled trials. Prog Cardiovasc Dis 29 (Suppl 1): 99Google Scholar
  20. 20.
    Ames RP, Hill P (1976) Increase in serum lipids during treatment of hypertension with chlorthalidone. Lancet 1: 721PubMedCrossRefGoogle Scholar
  21. 21.
    Sesoko S, Keneko Y (1985) Cough associated with use of captopril. Arch Intern Med 145: 15–24CrossRefGoogle Scholar
  22. 22.
    Sakaguchi K, Chai SY, Jackson B, Johnston CJ, Mendelsohn FAO (1988) Inhibition of tissue angiotensin converting enzyme. Hypertension 11 /3: 230–238PubMedCrossRefGoogle Scholar
  23. 23.
    Elliot WJ, Murphy MB, Karp R (1988) Long-term preservation of renal function in hypertensive cardiac transplant recipients with enalapril and a diuretic. (Proceedings; International Symposium on ACE Inhibition, London; Abstract F068 )Google Scholar
  24. 24.
    Kingma JH, Van Gilst WH, Graeff P de, Louwerenburg HW, Six AJ, Wesseling H (1988) Captopril during thrombolysis in myocardial infarction: Feasibility, tolerance and beneficial neurohumoral effects. (Proceedings; International Symposium on ACE Inhibition, London; Abstract F182 )Google Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1990

Authors and Affiliations

  • K. O. Stumpe

There are no affiliations available

Personalised recommendations